Physician

Magdalena Barbara Sikora, M.D.

According to 2025 Medicare claims, Magdalena Sikora, M.D. (NPI: 1598896110) practices nephrology in the Lawton, OK market, with the plurality of this provider's patient population coming from Comanche, OK. This provider's primary affiliated billing organization is DALLAS RENAL GROUP PA (NPI: 1629186168; TIN: 202199650) and primary practice location at 73505-5977. Sikora is affiliated with the Lifecare ACO LLC (ACO ID: A3644), participating under the MSSP model.

Sikora's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 863 traditional Medicare patients, billed 5,847 HCPCS/CPT codes, and received $343,097 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,540 prescription claims across 317 beneficiaries totaling $148,951 in drug costs, led by Sevelamer Carbonate (Sevelamer Carbonate). DME data shows 129 claims. Open Payments data shows 32 records totaling $687. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $139,133 to $343,097. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $135,668 and ending at $148,951. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,920 to $1,962.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	329	1,640	$139,133
2016	379	1,599	$142,312
2017	414	1,648	$146,471
2018	502	2,008	$170,507
2019	840	3,232	$322,346
2020	1,040	4,021	$454,584
2021	961	3,225	$378,743
2022	917	3,209	$256,531
2023	891	5,003	$318,118
2024	863	5,847	$343,097

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	651	$135,668
2016	93	694	$170,556
2017	114	811	$229,735
2018	127	868	$161,407
2019	158	1,040	$170,384
2020	215	1,234	$290,726
2021	235	1,375	$261,577
2022	250	1,350	$233,005
2023	269	1,424	$258,877
2024	317	1,540	$148,951

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$64
2018	N/R	33	$462
2019	N/R	13	$139
2020	N/R	60	$1,242
2021	N/R	128	$8,011
2022	N/R	61	$2,622
2023	N/R	12	$110
2024	N/R	129	$3,343

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	102	265	$258
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	105	128	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	486	985	$39
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	125	1,038	$34
99458	Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes	114	1,488	$28

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sevelamer Carbonate	Sevelamer Carbonate	58	3,008	$20,024
Jardiance	Empagliflozin	11	750	$14,776
Eliquis	Apixaban	13	690	$12,373
Ozempic	Semaglutide	13	458	$11,890
Clonidine	Clonidine	27	1,520	$3,442

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	27	$1,566
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	25	$790
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	29	$527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	37	$451
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	32	$687	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Magdalena Barbara Sikora, M.D.?

Tedicare shows public-source Medicare data for Magdalena Barbara Sikora, M.D. (NPI 1598896110), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Magdalena Barbara Sikora, M.D. have ACO affiliation data?

Magdalena Barbara Sikora, M.D. is shown with ACO affiliation data for Lifecare ACO LLC (MSSP, ACO ID A3644).

What billing organization is linked to Magdalena Barbara Sikora, M.D.?

Magdalena Barbara Sikora, M.D. is linked to DALLAS RENAL GROUP PA (billing NPI 1629186168) in the available physician profile data.

Does Magdalena Barbara Sikora, M.D. have Open Payments data?

Magdalena Barbara Sikora, M.D. has 32 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.